Phathom Pharmaceuticals, Inc. (PHAT)
| Market Cap | 522.65M -46.7% |
| Revenue (ttm) | 274.88M +86.8% |
| Net Income | -83.00M |
| EPS | -1.02 |
| Shares Out | 79.43M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 911,732 |
| Open | 7.00 |
| Previous Close | 6.28 |
| Day's Range | 6.01 - 7.00 |
| 52-Week Range | 5.02 - 18.31 |
| Beta | 0.50 |
| Analysts | Buy |
| Price Target | 19.64 (+198.48%) |
| Earnings Date | Oct 29, 2026 |
About PHAT
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-eros... [Read more]
Financial Performance
In 2025, Phathom Pharmaceuticals's revenue was $175.11 million, an increase of 216.93% compared to the previous year's $55.25 million. Losses were -$221.25 million, -33.82% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for PHAT stock is "Buy." The 12-month stock price target is $19.64, which is an increase of 198.48% from the latest price.
News
Phathom Pharmaceuticals Earnings Call Transcript: Q3 2026
Q3 revenue rose 71% YoY to $84.7 million, with a second consecutive quarter of adjusted operating profit and positive operating cash flow. Access initiatives and reiterated FY26 guidance support momentum, while exclusivity litigation and pipeline milestones remain key uncertainties.
Phathom Pharmaceuticals Earnings release: Q3 2026
Phathom Pharmaceuticals released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Phathom Pharmaceuticals Quarterly report: Q3 2026
Phathom Pharmaceuticals has published its Q3 2026 quarterly earnings report on October 29, 2026.
Phathom Pharmaceuticals Slides: Q3 2026
Phathom Pharmaceuticals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Phathom Pharmaceuticals Slides: Corporate presentation
Phathom Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on October 29, 2026.
Phathom Pharmaceuticals reports Q3 EPS 4c, consensus 3c
Reports Q3 revenue $84.72M, consensus $84.82M. “We are pleased to report continued solid revenue growth and improved operating profitability for the third quarter,” said Steve Basta, President and Chi...
Phathom Pharmaceuticals backs FY26 revenue view $310M-$325M, consensus $315.24M
Backs FY26 operating expenses $235M-$245M. “Our third quarter results reflect Phathom’s significant financial transformation, with revenue growth of 71% year over year and positive cash flow from oper...
Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Over 2 million total VOQUEZNA® prescriptions filled through October 16, 2026 Q3 2026 net revenues of $84.7 million increased 71% vs. Q3 2025 and 14% vs.
Phathom Pharmaceuticals provides update on FDA litigation
Phathom Pharmaceuticals (PHAT) announced the FDA’s establishment of a public docket to solicit comment on legal and regulatory questions regarding certain issues raised by a filer of an abbreviated ne...
Phathom Pharmaceuticals Provides Update on FDA Litigation
FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastroint...
Cantor sees low odds of suit leading FDA to reverse on Phathom exclusivity
After Phathom Pharmaceuticals (PHAT) announced that BDR Pharmaceuticals filed a suit against the FDA, challenging the agency’s refusal to receive an abbreviated new drug application that referenced Ph...
Phathom Pharmaceuticals gives update on litigation filed by BDR Pharmaceuticals
Phathom Pharmaceuticals (PHAT) announced that BDR Pharmaceuticals has filed suit against the FDA and related Federal Defendants in the United States District Court for the District of Columbia, princi...
Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA
FLORHAM PARK, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastroint...
Phathom Pharmaceuticals price target lowered to $15 from $20 at Craig-Hallum
Craig-Hallum analyst Chase Knickerbocker lowered the firm’s price target on Phathom Pharmaceuticals (PHAT) to $15 from $20 and keeps a Buy rating on the shares. The firm is adjusting its…
Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026
Management to host conference call on Thursday, October 29, 2026, at 8:00 am EDT Management to host conference call on Thursday, October 29, 2026, at 8:00 am EDT
Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting
Three scientific presentations will highlight new analyses of VOQUEZNA® (vonoprazan) in GERD, including real-world patient characteristics, efficacy across BMI subgroups, and cost-effectiveness in Ero...
Phathom Pharmaceuticals announces initiation of Phase 3 study of VOQUEZNA
Phathom Pharmaceuticals (PHAT) announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed investigational dosing regimen of VOQUEZNA tabl...
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
Initiation of registrational Phase 3 study of VOQUEZNA® (vonoprazan) for as-needed (PRN) use in Non-Erosive Reflux Disease (NERD) builds on previously reported positive Phase 2 data Topline results ex...
PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $PHAT--PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law.
Phathom Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Voquezna’s strong commercial momentum is driven by high efficacy, expanding coverage, and targeted growth in GI practices. Financial performance is robust, with operating profit achieved ahead of schedule and positive cash flow expected next year. Pipeline expansion into EoE and as-needed GERD therapy, along with future OTC potential, positions the product for continued growth.
Phathom Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
A new therapy for gastroesophageal reflux is driving rapid revenue growth and profitability, with peak sales potential exceeding $2B across specialist and primary care channels. Physician adoption is strong, aided by streamlined access, and future growth is supported by pipeline expansion, long exclusivity, and plans for OTC transition.
Leerink starts Phathom Pharmaceuticals at Market Perform on limited upside
As previously reported, Leerink initiated coverage of Phathom Pharmaceuticals (PHAT) with a Market Perform rating and $10 price target Voquenza competes in the “highly genericized” gastroesophageal re...
Phathom Pharmaceuticals initiated with a Market Perform at Leerink
Leerink initiated coverage of Phathom Pharmaceuticals (PHAT) with a Market Perform rating and $10 price target
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastroin...
Phathom Pharmaceuticals price target lowered to $14 from $18 at Barclays
Barclays lowered the firm’s price target on Phathom Pharmaceuticals (PHAT) to $14 from $18 and keeps an Overweight rating on the shares.